Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 72 | 2024 | 9031 | 3.950 |
Why?
|
Glioblastoma | 38 | 2024 | 3482 | 3.100 |
Why?
|
Glioma | 26 | 2024 | 3455 | 2.870 |
Why?
|
Skull Base Neoplasms | 6 | 2024 | 270 | 1.780 |
Why?
|
Isocitrate Dehydrogenase | 15 | 2024 | 938 | 1.740 |
Why?
|
Meningioma | 15 | 2024 | 1218 | 1.610 |
Why?
|
Craniotomy | 13 | 2021 | 741 | 1.590 |
Why?
|
Meningeal Neoplasms | 11 | 2024 | 1248 | 1.250 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2018 | 891 | 1.180 |
Why?
|
Hydrocephalus, Normal Pressure | 3 | 2024 | 100 | 1.120 |
Why?
|
Chondrosarcoma | 3 | 2023 | 296 | 1.050 |
Why?
|
Astrocytoma | 5 | 2024 | 775 | 1.020 |
Why?
|
Chordoma | 3 | 2023 | 347 | 1.000 |
Why?
|
Immunotherapy, Adoptive | 7 | 2024 | 1469 | 1.000 |
Why?
|
Oncolytic Virotherapy | 5 | 2017 | 516 | 0.860 |
Why?
|
Immunotherapy | 11 | 2022 | 4652 | 0.800 |
Why?
|
Cancer Vaccines | 4 | 2019 | 1051 | 0.710 |
Why?
|
Evoked Potentials, Motor | 2 | 2021 | 464 | 0.670 |
Why?
|
Neurosurgical Procedures | 9 | 2024 | 2072 | 0.650 |
Why?
|
Gait Disorders, Neurologic | 1 | 2021 | 240 | 0.630 |
Why?
|
Cerebral Ventricles | 1 | 2021 | 542 | 0.620 |
Why?
|
Receptors, OX40 | 1 | 2018 | 44 | 0.600 |
Why?
|
Spinal Neoplasms | 2 | 2017 | 716 | 0.600 |
Why?
|
Monitoring, Intraoperative | 3 | 2021 | 942 | 0.590 |
Why?
|
Craniopharyngioma | 4 | 2023 | 277 | 0.570 |
Why?
|
Mutation | 28 | 2024 | 30054 | 0.510 |
Why?
|
Neurosurgery | 4 | 2022 | 679 | 0.490 |
Why?
|
Combined Modality Therapy | 13 | 2022 | 8528 | 0.490 |
Why?
|
Fibula | 1 | 2017 | 266 | 0.480 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2018 | 4369 | 0.460 |
Why?
|
Evoked Potentials, Somatosensory | 3 | 2021 | 246 | 0.430 |
Why?
|
Tumor Microenvironment | 8 | 2024 | 3877 | 0.420 |
Why?
|
T-Lymphocytes | 8 | 2024 | 10194 | 0.420 |
Why?
|
Paranasal Sinus Neoplasms | 4 | 2023 | 242 | 0.420 |
Why?
|
Pituitary Neoplasms | 5 | 2023 | 1324 | 0.420 |
Why?
|
Bone Transplantation | 1 | 2017 | 929 | 0.400 |
Why?
|
Esthesioneuroblastoma, Olfactory | 4 | 2023 | 58 | 0.400 |
Why?
|
Humans | 152 | 2024 | 761572 | 0.400 |
Why?
|
Nasal Cavity | 4 | 2024 | 304 | 0.390 |
Why?
|
Therapeutic Irrigation | 1 | 2013 | 292 | 0.390 |
Why?
|
Telomerase | 4 | 2024 | 745 | 0.380 |
Why?
|
Oligodendroglioma | 3 | 2019 | 279 | 0.380 |
Why?
|
Kaplan-Meier Estimate | 11 | 2018 | 6484 | 0.350 |
Why?
|
Epidural Neoplasms | 1 | 2010 | 24 | 0.350 |
Why?
|
Central Nervous System Vascular Malformations | 1 | 2011 | 140 | 0.350 |
Why?
|
Models, Immunological | 1 | 2012 | 513 | 0.340 |
Why?
|
Orbit | 1 | 2013 | 457 | 0.330 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2011 | 170 | 0.330 |
Why?
|
Scalp | 1 | 2012 | 389 | 0.330 |
Why?
|
Spinal Cord Compression | 1 | 2011 | 235 | 0.330 |
Why?
|
Nose Neoplasms | 3 | 2023 | 249 | 0.330 |
Why?
|
Aged | 50 | 2024 | 169310 | 0.320 |
Why?
|
Middle Aged | 64 | 2024 | 220920 | 0.320 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2024 | 9280 | 0.320 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2012 | 495 | 0.320 |
Why?
|
Retrospective Studies | 38 | 2024 | 80646 | 0.310 |
Why?
|
Methylene Blue | 3 | 2014 | 155 | 0.310 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2009 | 277 | 0.310 |
Why?
|
Nose | 2 | 2024 | 521 | 0.310 |
Why?
|
Vaccination | 2 | 2018 | 3384 | 0.310 |
Why?
|
Osteotomy | 1 | 2013 | 837 | 0.290 |
Why?
|
Adult | 55 | 2024 | 221203 | 0.290 |
Why?
|
Neoplastic Stem Cells | 6 | 2017 | 1349 | 0.290 |
Why?
|
Eye Diseases | 1 | 2013 | 653 | 0.290 |
Why?
|
Societies, Medical | 2 | 2022 | 3905 | 0.280 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2016 | 2827 | 0.280 |
Why?
|
Tumor Cells, Cultured | 4 | 2015 | 6132 | 0.280 |
Why?
|
Craniocerebral Trauma | 1 | 2011 | 490 | 0.280 |
Why?
|
Radiosurgery | 3 | 2013 | 1342 | 0.280 |
Why?
|
Loss of Heterozygosity | 1 | 2009 | 662 | 0.280 |
Why?
|
Decompression, Surgical | 2 | 2018 | 607 | 0.270 |
Why?
|
Postoperative Care | 1 | 2012 | 1468 | 0.260 |
Why?
|
Male | 69 | 2024 | 360842 | 0.260 |
Why?
|
Female | 72 | 2024 | 392686 | 0.260 |
Why?
|
Immunologic Factors | 1 | 2015 | 1589 | 0.250 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2020 | 1784 | 0.250 |
Why?
|
Disease Progression | 15 | 2023 | 13510 | 0.250 |
Why?
|
Neoplasms, Experimental | 2 | 2019 | 1229 | 0.250 |
Why?
|
Aged, 80 and over | 24 | 2024 | 58986 | 0.240 |
Why?
|
Computers, Handheld | 1 | 2006 | 210 | 0.240 |
Why?
|
Carcinoma, Papillary | 1 | 2010 | 785 | 0.240 |
Why?
|
Central Nervous System Neoplasms | 2 | 2024 | 916 | 0.240 |
Why?
|
Cerebellar Neoplasms | 2 | 2022 | 586 | 0.230 |
Why?
|
Patient Transfer | 1 | 2011 | 794 | 0.230 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2005 | 195 | 0.230 |
Why?
|
Epidural Abscess | 1 | 2005 | 94 | 0.220 |
Why?
|
Healthcare Disparities | 2 | 2010 | 3358 | 0.220 |
Why?
|
Pseudotumor Cerebri | 1 | 2005 | 108 | 0.220 |
Why?
|
Multivariate Analysis | 6 | 2018 | 12059 | 0.220 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4580 | 0.220 |
Why?
|
Dendritic Cells | 2 | 2019 | 2747 | 0.220 |
Why?
|
Socioeconomic Factors | 4 | 2023 | 7827 | 0.220 |
Why?
|
Treatment Outcome | 21 | 2024 | 64684 | 0.220 |
Why?
|
Immunity, Innate | 2 | 2012 | 3066 | 0.210 |
Why?
|
Antibodies, Monoclonal | 3 | 2015 | 9177 | 0.210 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2024 | 326 | 0.210 |
Why?
|
Brain Diseases | 2 | 2024 | 1545 | 0.210 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 2 | 2020 | 324 | 0.200 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2005 | 485 | 0.190 |
Why?
|
Transplantation, Autologous | 2 | 2017 | 2115 | 0.190 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2007 | 1092 | 0.190 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2001 | 44 | 0.190 |
Why?
|
Antineoplastic Agents | 7 | 2023 | 13642 | 0.190 |
Why?
|
Melanoma | 2 | 2022 | 5709 | 0.190 |
Why?
|
Cytokines | 2 | 2015 | 7396 | 0.190 |
Why?
|
Nose Diseases | 2 | 2020 | 79 | 0.180 |
Why?
|
Immunohistochemistry | 8 | 2017 | 11076 | 0.180 |
Why?
|
Bacterial Infections | 1 | 2009 | 1391 | 0.180 |
Why?
|
Neoplasm Proteins | 3 | 2021 | 3617 | 0.180 |
Why?
|
Aerosols | 2 | 2020 | 635 | 0.180 |
Why?
|
Antineoplastic Agents, Alkylating | 4 | 2022 | 617 | 0.180 |
Why?
|
Prognosis | 18 | 2024 | 29629 | 0.180 |
Why?
|
Spinal Cord Neoplasms | 2 | 2014 | 263 | 0.180 |
Why?
|
Neoplasms | 4 | 2024 | 22173 | 0.180 |
Why?
|
Mice | 20 | 2024 | 81533 | 0.180 |
Why?
|
Neoplasm Transplantation | 2 | 2016 | 2016 | 0.180 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2012 | 2791 | 0.180 |
Why?
|
Motor Cortex | 2 | 2021 | 1007 | 0.170 |
Why?
|
Lateral Ventricles | 1 | 2001 | 146 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2057 | 0.170 |
Why?
|
Molecular Targeted Therapy | 5 | 2019 | 2811 | 0.170 |
Why?
|
Colloid Cysts | 1 | 2019 | 6 | 0.170 |
Why?
|
Insurance Coverage | 1 | 2011 | 1940 | 0.170 |
Why?
|
Animals | 28 | 2024 | 168467 | 0.170 |
Why?
|
Single-Cell Analysis | 5 | 2019 | 2450 | 0.170 |
Why?
|
Critical Care | 1 | 2012 | 2697 | 0.170 |
Why?
|
Intraoperative Complications | 2 | 2019 | 1166 | 0.160 |
Why?
|
Surgical Wound Infection | 2 | 2008 | 1529 | 0.160 |
Why?
|
Brain Mapping | 4 | 2021 | 6635 | 0.160 |
Why?
|
Intensive Care Units | 1 | 2012 | 3744 | 0.160 |
Why?
|
Temporal Lobe | 3 | 2018 | 1695 | 0.160 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 2 | 2016 | 83 | 0.160 |
Why?
|
Hospital Mortality | 3 | 2010 | 5293 | 0.160 |
Why?
|
Gene Amplification | 3 | 2018 | 1089 | 0.160 |
Why?
|
Endoscopy | 3 | 2020 | 1851 | 0.150 |
Why?
|
Cell Line, Tumor | 10 | 2024 | 16986 | 0.150 |
Why?
|
Reoperation | 3 | 2018 | 4303 | 0.150 |
Why?
|
Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
Neuronavigation | 1 | 2019 | 166 | 0.150 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2024 | 2547 | 0.150 |
Why?
|
Karnofsky Performance Status | 1 | 2018 | 166 | 0.150 |
Why?
|
Tumor Burden | 2 | 2014 | 1893 | 0.150 |
Why?
|
Radiation Injuries | 2 | 2019 | 1189 | 0.150 |
Why?
|
Disease Management | 2 | 2019 | 2508 | 0.150 |
Why?
|
Neurosecretory Systems | 1 | 2019 | 223 | 0.150 |
Why?
|
Guanidines | 1 | 2018 | 194 | 0.150 |
Why?
|
Postoperative Complications | 9 | 2021 | 15633 | 0.140 |
Why?
|
Medulloblastoma | 1 | 2022 | 678 | 0.140 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 11 | 2021 | 36429 | 0.140 |
Why?
|
Mice, SCID | 6 | 2019 | 2626 | 0.140 |
Why?
|
Explosions | 1 | 2017 | 108 | 0.140 |
Why?
|
Supratentorial Neoplasms | 2 | 2011 | 159 | 0.140 |
Why?
|
Survival Analysis | 7 | 2019 | 10090 | 0.140 |
Why?
|
Dexamethasone | 1 | 2024 | 1948 | 0.140 |
Why?
|
Urinary Incontinence | 1 | 2021 | 489 | 0.140 |
Why?
|
Antibodies, Bispecific | 1 | 2019 | 196 | 0.140 |
Why?
|
Glasgow Coma Scale | 2 | 2011 | 580 | 0.140 |
Why?
|
Brachytherapy | 2 | 2019 | 1223 | 0.140 |
Why?
|
Meningomyelocele | 1 | 2018 | 171 | 0.140 |
Why?
|
Thyroid Neoplasms | 1 | 2010 | 2332 | 0.130 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2019 | 3603 | 0.130 |
Why?
|
4-1BB Ligand | 1 | 2016 | 29 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2020 | 491 | 0.130 |
Why?
|
Calcaneus | 1 | 2017 | 142 | 0.130 |
Why?
|
Disease Models, Animal | 8 | 2024 | 18253 | 0.130 |
Why?
|
Databases, Factual | 4 | 2014 | 7967 | 0.130 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor | 1 | 2016 | 66 | 0.130 |
Why?
|
OX40 Ligand | 1 | 2016 | 55 | 0.130 |
Why?
|
Graves Ophthalmopathy | 1 | 2018 | 133 | 0.130 |
Why?
|
Foot Injuries | 1 | 2017 | 149 | 0.130 |
Why?
|
Follow-Up Studies | 12 | 2024 | 39107 | 0.130 |
Why?
|
Language | 2 | 2018 | 1540 | 0.130 |
Why?
|
Young Adult | 15 | 2024 | 59255 | 0.120 |
Why?
|
Lymphoma | 1 | 2024 | 1901 | 0.120 |
Why?
|
Critical Pathways | 1 | 2019 | 474 | 0.120 |
Why?
|
Demeclocycline | 1 | 2014 | 5 | 0.120 |
Why?
|
Herpesvirus 1, Human | 2 | 2012 | 753 | 0.120 |
Why?
|
Diagnosis, Differential | 4 | 2021 | 12975 | 0.120 |
Why?
|
NAD | 2 | 2016 | 614 | 0.120 |
Why?
|
Rhabdoid Tumor | 1 | 2017 | 210 | 0.120 |
Why?
|
Up-Regulation | 1 | 2024 | 4124 | 0.120 |
Why?
|
Burnout, Professional | 1 | 2023 | 704 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 899 | 0.120 |
Why?
|
Mice, Inbred C57BL | 5 | 2019 | 22172 | 0.120 |
Why?
|
Thalamus | 1 | 2021 | 1047 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2024 | 3492 | 0.120 |
Why?
|
Antigens, Neoplasm | 2 | 2019 | 1993 | 0.120 |
Why?
|
Tibial Fractures | 1 | 2017 | 273 | 0.120 |
Why?
|
Hemangioblastoma | 1 | 2014 | 62 | 0.120 |
Why?
|
Dacarbazine | 2 | 2008 | 559 | 0.120 |
Why?
|
Drugs, Investigational | 1 | 2016 | 212 | 0.120 |
Why?
|
Internet | 3 | 2011 | 3093 | 0.120 |
Why?
|
K562 Cells | 1 | 2016 | 642 | 0.110 |
Why?
|
Sequence Analysis, RNA | 3 | 2017 | 2020 | 0.110 |
Why?
|
Odds Ratio | 3 | 2019 | 9646 | 0.110 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2014 | 39 | 0.110 |
Why?
|
United States | 11 | 2024 | 72335 | 0.110 |
Why?
|
Blast Injuries | 1 | 2017 | 322 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1374 | 0.110 |
Why?
|
Disease-Free Survival | 7 | 2022 | 6815 | 0.110 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2017 | 455 | 0.110 |
Why?
|
Cadaver | 4 | 2020 | 1358 | 0.110 |
Why?
|
Posture | 1 | 2017 | 957 | 0.110 |
Why?
|
Ankle Injuries | 1 | 2017 | 339 | 0.110 |
Why?
|
Speech | 1 | 2018 | 554 | 0.110 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 305 | 0.110 |
Why?
|
Parkinsonian Disorders | 1 | 2016 | 284 | 0.100 |
Why?
|
Otolaryngology | 1 | 2020 | 693 | 0.100 |
Why?
|
Bone Neoplasms | 2 | 2017 | 2529 | 0.100 |
Why?
|
Nicardipine | 1 | 2012 | 60 | 0.100 |
Why?
|
Skin Neoplasms | 1 | 2012 | 5821 | 0.100 |
Why?
|
Infant | 6 | 2023 | 36192 | 0.100 |
Why?
|
Chromosomes, Artificial, Bacterial | 1 | 2012 | 123 | 0.100 |
Why?
|
Adolescent | 13 | 2023 | 88324 | 0.100 |
Why?
|
Mucous Membrane | 1 | 2016 | 659 | 0.100 |
Why?
|
Transplantation, Isogeneic | 1 | 2012 | 248 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3086 | 0.100 |
Why?
|
Medically Uninsured | 1 | 2018 | 836 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2019 | 2456 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3206 | 0.100 |
Why?
|
Skull | 2 | 2008 | 818 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 11742 | 0.100 |
Why?
|
Injections, Intraventricular | 1 | 2012 | 225 | 0.100 |
Why?
|
Interferon-gamma | 2 | 2012 | 3162 | 0.100 |
Why?
|
Patient Advocacy | 1 | 2014 | 360 | 0.100 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2012 | 61 | 0.100 |
Why?
|
Injections, Intraperitoneal | 1 | 2012 | 413 | 0.100 |
Why?
|
Breast Neoplasms | 3 | 2024 | 21017 | 0.100 |
Why?
|
Protons | 3 | 2023 | 1116 | 0.100 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 619 | 0.090 |
Why?
|
Survival Rate | 5 | 2024 | 12725 | 0.090 |
Why?
|
Legislation, Medical | 1 | 2011 | 98 | 0.090 |
Why?
|
Diabetes Mellitus | 3 | 2018 | 5841 | 0.090 |
Why?
|
Gamma Rays | 1 | 2012 | 318 | 0.090 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2018 | 954 | 0.090 |
Why?
|
Olfactory Mucosa | 1 | 2011 | 101 | 0.090 |
Why?
|
Electric Stimulation | 4 | 2019 | 1736 | 0.090 |
Why?
|
Simplexvirus | 2 | 2017 | 803 | 0.090 |
Why?
|
Child, Preschool | 5 | 2023 | 42230 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.090 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2012 | 553 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2015 | 610 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2014 | 767 | 0.090 |
Why?
|
Texas | 1 | 2011 | 404 | 0.090 |
Why?
|
Cohort Studies | 8 | 2020 | 41493 | 0.090 |
Why?
|
Risk Factors | 12 | 2021 | 74213 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2057 | 0.090 |
Why?
|
Primary Health Care | 1 | 2006 | 4686 | 0.090 |
Why?
|
Coloring Agents | 1 | 2012 | 562 | 0.090 |
Why?
|
Somatosensory Cortex | 1 | 2014 | 512 | 0.090 |
Why?
|
Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 2009 | 23 | 0.080 |
Why?
|
Pathology, Molecular | 1 | 2013 | 328 | 0.080 |
Why?
|
Ki-67 Antigen | 3 | 2017 | 629 | 0.080 |
Why?
|
Surgical Flaps | 2 | 2011 | 1671 | 0.080 |
Why?
|
Southeastern United States | 3 | 2018 | 91 | 0.080 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 1962 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3201 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2020 | 6935 | 0.080 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1027 | 0.080 |
Why?
|
Promoter Regions, Genetic | 4 | 2024 | 5790 | 0.080 |
Why?
|
Calcium Channel Blockers | 1 | 2012 | 694 | 0.080 |
Why?
|
Salivary Gland Neoplasms | 1 | 2013 | 304 | 0.080 |
Why?
|
Neuroprotective Agents | 1 | 2016 | 957 | 0.080 |
Why?
|
Sphenoid Sinus | 1 | 2009 | 99 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8552 | 0.080 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2011 | 695 | 0.080 |
Why?
|
RNA Transport | 1 | 2008 | 45 | 0.080 |
Why?
|
Centralized Hospital Services | 2 | 2005 | 18 | 0.080 |
Why?
|
Education, Medical, Continuing | 2 | 2011 | 823 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 2 | 2017 | 2803 | 0.080 |
Why?
|
Age Factors | 3 | 2014 | 18398 | 0.080 |
Why?
|
Child | 9 | 2023 | 80156 | 0.080 |
Why?
|
Enzyme Inhibitors | 2 | 2015 | 3713 | 0.080 |
Why?
|
Bone Marrow | 1 | 2018 | 2911 | 0.080 |
Why?
|
Pneumocephalus | 1 | 2008 | 47 | 0.080 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2557 | 0.070 |
Why?
|
Ependymoma | 1 | 2011 | 320 | 0.070 |
Why?
|
Genotype | 3 | 2018 | 12990 | 0.070 |
Why?
|
Tracheotomy | 1 | 2008 | 167 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2014 | 946 | 0.070 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 14666 | 0.070 |
Why?
|
Spinal Cord | 1 | 2016 | 1819 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1835 | 0.070 |
Why?
|
Neurofibromatosis 2 | 1 | 2011 | 385 | 0.070 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2009 | 262 | 0.070 |
Why?
|
Feedback | 1 | 2010 | 791 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12463 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 3080 | 0.070 |
Why?
|
Conscious Sedation | 1 | 2011 | 532 | 0.070 |
Why?
|
Microscopy, Confocal | 1 | 2012 | 1971 | 0.070 |
Why?
|
Transgenes | 1 | 2010 | 1010 | 0.070 |
Why?
|
Brain | 5 | 2019 | 27120 | 0.070 |
Why?
|
Gene Silencing | 2 | 2014 | 1509 | 0.070 |
Why?
|
Seizures | 1 | 2019 | 2957 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 6 | 2019 | 20571 | 0.060 |
Why?
|
Helium | 1 | 2006 | 119 | 0.060 |
Why?
|
Trauma Centers | 1 | 2011 | 937 | 0.060 |
Why?
|
Skull Base | 2 | 2023 | 292 | 0.060 |
Why?
|
Antigens, Viral | 1 | 2010 | 988 | 0.060 |
Why?
|
Cerebral Cortex | 3 | 2024 | 5779 | 0.060 |
Why?
|
Particle Accelerators | 1 | 2006 | 174 | 0.060 |
Why?
|
Thoracic Vertebrae | 1 | 2010 | 597 | 0.060 |
Why?
|
Physicians | 1 | 2023 | 4591 | 0.060 |
Why?
|
Histones | 1 | 2016 | 2580 | 0.060 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3597 | 0.060 |
Why?
|
Polymerase Chain Reaction | 4 | 2020 | 6075 | 0.060 |
Why?
|
Patient Admission | 1 | 2012 | 1367 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2047 | 0.060 |
Why?
|
Quality of Health Care | 2 | 2011 | 4330 | 0.060 |
Why?
|
Massachusetts | 2 | 2023 | 8830 | 0.060 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5485 | 0.060 |
Why?
|
Prospective Studies | 6 | 2024 | 54426 | 0.060 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2008 | 1351 | 0.060 |
Why?
|
Physicians, Primary Care | 1 | 2011 | 623 | 0.060 |
Why?
|
Gene Transfer Techniques | 1 | 2010 | 1206 | 0.060 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 2645 | 0.060 |
Why?
|
Airway Obstruction | 1 | 2009 | 661 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5428 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2927 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2006 | 882 | 0.060 |
Why?
|
Glucose | 1 | 2016 | 4346 | 0.060 |
Why?
|
Exosomes | 1 | 2008 | 424 | 0.060 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 732 | 0.060 |
Why?
|
Contrast Media | 2 | 2014 | 5311 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2015 | 3639 | 0.060 |
Why?
|
Signal Transduction | 6 | 2019 | 23447 | 0.060 |
Why?
|
Bipolar Disorder | 1 | 2021 | 5092 | 0.060 |
Why?
|
Immunity | 1 | 2010 | 996 | 0.060 |
Why?
|
Microsatellite Instability | 1 | 2007 | 716 | 0.060 |
Why?
|
Deglutition Disorders | 1 | 2009 | 625 | 0.060 |
Why?
|
Feasibility Studies | 3 | 2021 | 5247 | 0.050 |
Why?
|
Cervical Vertebrae | 1 | 2009 | 980 | 0.050 |
Why?
|
Intraoperative Period | 2 | 2015 | 510 | 0.050 |
Why?
|
Hospitals | 2 | 2019 | 3882 | 0.050 |
Why?
|
Carcinoma | 1 | 2014 | 2330 | 0.050 |
Why?
|
Biopsy | 4 | 2019 | 6766 | 0.050 |
Why?
|
Population Groups | 1 | 2023 | 208 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2006 | 12148 | 0.050 |
Why?
|
Genetic Variation | 2 | 2015 | 6567 | 0.050 |
Why?
|
Brain Infarction | 1 | 2004 | 290 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2024 | 8601 | 0.050 |
Why?
|
Vaccines, Subunit | 1 | 2022 | 161 | 0.050 |
Why?
|
Regression Analysis | 2 | 2017 | 6344 | 0.050 |
Why?
|
Face | 1 | 2008 | 1026 | 0.050 |
Why?
|
Radiography | 2 | 2011 | 6965 | 0.050 |
Why?
|
Treatment Failure | 2 | 2019 | 2644 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 1613 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2017 | 5305 | 0.050 |
Why?
|
Embryonic Stem Cells | 1 | 2009 | 1263 | 0.050 |
Why?
|
Patient Participation | 1 | 2010 | 1445 | 0.050 |
Why?
|
Foramen Magnum | 1 | 2021 | 41 | 0.050 |
Why?
|
Depression | 1 | 2021 | 8124 | 0.050 |
Why?
|
Image Enhancement | 1 | 2012 | 2885 | 0.050 |
Why?
|
Cell Proliferation | 5 | 2017 | 10448 | 0.050 |
Why?
|
Leukocyte Count | 1 | 2005 | 1596 | 0.050 |
Why?
|
Cranial Fossa, Anterior | 2 | 2011 | 13 | 0.050 |
Why?
|
Fever | 2 | 2007 | 1618 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2007 | 1349 | 0.050 |
Why?
|
Postoperative Period | 2 | 2020 | 1814 | 0.050 |
Why?
|
Sneezing | 1 | 2020 | 17 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 641 | 0.040 |
Why?
|
Intubation, Intratracheal | 1 | 2008 | 1333 | 0.040 |
Why?
|
Spinal Fusion | 1 | 2010 | 1286 | 0.040 |
Why?
|
Sex Factors | 1 | 2014 | 10553 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2010 | 3396 | 0.040 |
Why?
|
Cesium Radioisotopes | 1 | 2019 | 38 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 2008 | 9610 | 0.040 |
Why?
|
Dominance, Cerebral | 1 | 2001 | 623 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2011 | 1923 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2024 | 823 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2023 | 544 | 0.040 |
Why?
|
World Health Organization | 2 | 2015 | 1322 | 0.040 |
Why?
|
Cell Lineage | 2 | 2019 | 2556 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2014 | 12794 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2024 | 1745 | 0.040 |
Why?
|
New England | 1 | 2022 | 1054 | 0.040 |
Why?
|
Time Factors | 5 | 2015 | 39970 | 0.040 |
Why?
|
Length of Stay | 2 | 2010 | 6426 | 0.040 |
Why?
|
Biomedical Research | 1 | 2014 | 3429 | 0.040 |
Why?
|
RNA | 1 | 2008 | 2726 | 0.040 |
Why?
|
Calcinosis | 1 | 2007 | 1469 | 0.040 |
Why?
|
Infant, Newborn | 2 | 2011 | 26198 | 0.040 |
Why?
|
Neuroendoscopy | 1 | 2019 | 99 | 0.040 |
Why?
|
Cell Differentiation | 4 | 2019 | 11530 | 0.040 |
Why?
|
Models, Nursing | 1 | 2018 | 46 | 0.040 |
Why?
|
Remission Induction | 1 | 2023 | 2397 | 0.040 |
Why?
|
Health Resources | 1 | 2023 | 935 | 0.040 |
Why?
|
Mitotic Index | 1 | 2017 | 162 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 6992 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 1036 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2014 | 2510 | 0.040 |
Why?
|
DNA Mutational Analysis | 2 | 2020 | 4111 | 0.030 |
Why?
|
Phonetics | 1 | 2018 | 198 | 0.030 |
Why?
|
Lymphoid Tissue | 1 | 2018 | 445 | 0.030 |
Why?
|
Comorbidity | 1 | 2011 | 10508 | 0.030 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2004 | 1033 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2015 | 2707 | 0.030 |
Why?
|
Sphingosine | 1 | 2018 | 308 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2006 | 2220 | 0.030 |
Why?
|
Lymphopenia | 1 | 2018 | 281 | 0.030 |
Why?
|
Pentosyltransferases | 1 | 2015 | 62 | 0.030 |
Why?
|
Lysophospholipids | 1 | 2018 | 338 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 2019 | 1031 | 0.030 |
Why?
|
History, 21st Century | 1 | 2022 | 1567 | 0.030 |
Why?
|
Particle Size | 1 | 2020 | 1648 | 0.030 |
Why?
|
Incidence | 3 | 2017 | 21355 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2017 | 11121 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 15936 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2005 | 2421 | 0.030 |
Why?
|
Geriatrics | 1 | 2020 | 388 | 0.030 |
Why?
|
Epilepsy | 1 | 2011 | 3290 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4853 | 0.030 |
Why?
|
Registries | 1 | 2011 | 8224 | 0.030 |
Why?
|
Practice Guidelines as Topic | 2 | 2017 | 7391 | 0.030 |
Why?
|
Logistic Models | 1 | 2010 | 13255 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1827 | 0.030 |
Why?
|
Obesity | 2 | 2007 | 12947 | 0.030 |
Why?
|
Frozen Sections | 1 | 2015 | 153 | 0.030 |
Why?
|
Embolization, Therapeutic | 1 | 2004 | 1418 | 0.030 |
Why?
|
Research Design | 1 | 2010 | 6180 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 3514 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2015 | 241 | 0.030 |
Why?
|
Gene Expression Profiling | 3 | 2016 | 9420 | 0.030 |
Why?
|
Digoxin | 1 | 2015 | 246 | 0.030 |
Why?
|
Substantia Nigra | 1 | 2016 | 350 | 0.030 |
Why?
|
Semantics | 1 | 2018 | 613 | 0.030 |
Why?
|
Oximes | 1 | 2015 | 303 | 0.030 |
Why?
|
Endocytosis | 1 | 2018 | 957 | 0.030 |
Why?
|
Glutarates | 1 | 2015 | 243 | 0.030 |
Why?
|
History, 20th Century | 1 | 2022 | 2767 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2015 | 330 | 0.030 |
Why?
|
Valine | 1 | 2015 | 408 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2009 | 4026 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2017 | 945 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2012 | 20099 | 0.030 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2014 | 322 | 0.030 |
Why?
|
SOXB1 Transcription Factors | 1 | 2015 | 286 | 0.030 |
Why?
|
Co-Repressor Proteins | 1 | 2014 | 190 | 0.030 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2014 | 353 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26127 | 0.030 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2014 | 183 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2015 | 385 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2015 | 656 | 0.030 |
Why?
|
Comprehension | 1 | 2018 | 621 | 0.030 |
Why?
|
Leadership | 1 | 2022 | 1385 | 0.030 |
Why?
|
Spleen | 1 | 2018 | 2295 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2015 | 598 | 0.030 |
Why?
|
Quality of Life | 3 | 2019 | 13367 | 0.020 |
Why?
|
Glycolysis | 1 | 2016 | 835 | 0.020 |
Why?
|
Point Mutation | 1 | 2016 | 1595 | 0.020 |
Why?
|
Magnetics | 1 | 2014 | 599 | 0.020 |
Why?
|
Cerebrospinal Fluid Rhinorrhea | 1 | 2011 | 87 | 0.020 |
Why?
|
Brain Chemistry | 1 | 2014 | 960 | 0.020 |
Why?
|
Neuroglia | 1 | 2016 | 956 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 8002 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2015 | 1008 | 0.020 |
Why?
|
Hypertension | 1 | 2010 | 8540 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 2023 | 3839 | 0.020 |
Why?
|
Pyridones | 1 | 2015 | 809 | 0.020 |
Why?
|
Pandemics | 2 | 2020 | 8656 | 0.020 |
Why?
|
Blotting, Western | 1 | 2017 | 5035 | 0.020 |
Why?
|
Glutamic Acid | 1 | 2015 | 1176 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 615 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2015 | 3597 | 0.020 |
Why?
|
Sensory Thresholds | 1 | 2011 | 377 | 0.020 |
Why?
|
Dissection | 1 | 2011 | 298 | 0.020 |
Why?
|
Imidazoles | 1 | 2015 | 1180 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2014 | 738 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2012 | 847 | 0.020 |
Why?
|
Neural Stem Cells | 1 | 2016 | 888 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2022 | 3600 | 0.020 |
Why?
|
Risk Assessment | 3 | 2017 | 23996 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2811 | 0.020 |
Why?
|
Rural Health | 1 | 2010 | 296 | 0.020 |
Why?
|
Oropharynx | 1 | 2009 | 138 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1858 | 0.020 |
Why?
|
Molecular Biology | 1 | 2012 | 576 | 0.020 |
Why?
|
Military Personnel | 1 | 2017 | 1246 | 0.020 |
Why?
|
Oncogenes | 1 | 2014 | 1222 | 0.020 |
Why?
|
Microglia | 1 | 2017 | 1361 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2827 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 2020 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1136 | 0.020 |
Why?
|
Papillomaviridae | 1 | 2014 | 1119 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 2020 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5774 | 0.020 |
Why?
|
Autophagy | 1 | 2015 | 1326 | 0.020 |
Why?
|
Hypertrophy | 1 | 2009 | 561 | 0.020 |
Why?
|
Rural Health Services | 1 | 2011 | 384 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2832 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4244 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15266 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2226 | 0.020 |
Why?
|
Paranasal Sinuses | 1 | 2009 | 265 | 0.020 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2008 | 278 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3430 | 0.020 |
Why?
|
Brain Edema | 1 | 2011 | 604 | 0.020 |
Why?
|
Radiotherapy | 1 | 2013 | 1499 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2005 | 7407 | 0.020 |
Why?
|
Necrosis | 1 | 2010 | 1611 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2015 | 4280 | 0.020 |
Why?
|
DNA Modification Methylases | 1 | 2007 | 210 | 0.020 |
Why?
|
Metabolomics | 1 | 2015 | 1659 | 0.020 |
Why?
|
Fibroma | 1 | 2007 | 190 | 0.020 |
Why?
|
Cytoskeletal Proteins | 1 | 2011 | 1342 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2009 | 339 | 0.020 |
Why?
|
Tracheostomy | 1 | 2009 | 426 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2007 | 346 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12341 | 0.020 |
Why?
|
Medical Oncology | 1 | 2017 | 2321 | 0.020 |
Why?
|
Phenotype | 2 | 2014 | 16592 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2011 | 1400 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2016 | 8181 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2850 | 0.010 |
Why?
|
Recurrence | 1 | 2017 | 8466 | 0.010 |
Why?
|
Antigens, CD | 1 | 2015 | 4001 | 0.010 |
Why?
|
DNA Mismatch Repair | 1 | 2008 | 428 | 0.010 |
Why?
|
Health Care Costs | 1 | 2018 | 3242 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2015 | 2882 | 0.010 |
Why?
|
Frontal Lobe | 1 | 2011 | 1420 | 0.010 |
Why?
|
Glasgow Outcome Scale | 1 | 2004 | 104 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2015 | 3466 | 0.010 |
Why?
|
Reference Values | 1 | 2011 | 4920 | 0.010 |
Why?
|
Laryngoscopy | 1 | 2009 | 707 | 0.010 |
Why?
|
Equipment Design | 1 | 2012 | 3511 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4740 | 0.010 |
Why?
|
Glycoproteins | 1 | 2011 | 2203 | 0.010 |
Why?
|
Neurons | 1 | 2023 | 9463 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2385 | 0.010 |
Why?
|
Transcription Factors | 2 | 2014 | 12129 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2009 | 2898 | 0.010 |
Why?
|
Vasospasm, Intracranial | 1 | 2004 | 215 | 0.010 |
Why?
|
SEER Program | 1 | 2007 | 1450 | 0.010 |
Why?
|
Macrophages | 1 | 2017 | 5769 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7581 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4811 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4415 | 0.010 |
Why?
|
Virus Replication | 1 | 2009 | 2435 | 0.010 |
Why?
|
Linear Models | 1 | 2011 | 5872 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3801 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2319 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9489 | 0.010 |
Why?
|
Rats | 1 | 2016 | 23741 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2005 | 1626 | 0.010 |
Why?
|
Body Mass Index | 2 | 2007 | 12954 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5672 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7879 | 0.010 |
Why?
|
Life Style | 1 | 2010 | 3917 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10766 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 18965 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2644 | 0.010 |
Why?
|
Boston | 1 | 2011 | 9326 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2011 | 7054 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 9002 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2007 | 1303 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2010 | 3249 | 0.010 |
Why?
|
Intracranial Aneurysm | 1 | 2007 | 1285 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12690 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2008 | 3548 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2007 | 2567 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 15843 | 0.010 |
Why?
|
Patient Readmission | 1 | 2007 | 3271 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2009 | 6346 | 0.010 |
Why?
|
Prevalence | 1 | 2007 | 15732 | 0.010 |
Why?
|
Medicare | 1 | 2007 | 6770 | 0.000 |
Why?
|